Compounds > n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
Page last updated: 2024-09-03

n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Hyperplasia, Congenital

n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea has been researched along with Adrenal Hyperplasia, Congenital in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Auchus, RJ; Chang, AY; El-Maouche, D; Joyal, EG; Lin, VH; Merke, DP; Mohideen, P; Plaunt, MR; Turcu, AF; Vogiatzi, MG; Weintraub, L1
Speiser, PW1

Trials

1 trial(s) available for n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Hyperplasia, Congenital

ArticleYear
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
    The Journal of clinical endocrinology and metabolism, 2020, 08-01, Volume: 105, Issue:8

    Topics: 17-alpha-Hydroxyprogesterone; Administration, Oral; Adolescent; Adrenal Cortex; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Adult; Androstenedione; Biomarkers; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucocorticoids; Humans; Middle Aged; Treatment Outcome; Urea; Young Adult

2020

Other Studies

1 other study(ies) available for n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Hyperplasia, Congenital

ArticleYear
Invited Commentary: A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
    The Journal of clinical endocrinology and metabolism, 2020, 10-01, Volume: 105, Issue:10

    Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Humans; Urea

2020